<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-164476</identifier>
<setSpec>0003-3170</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Impact of endovascular treatment in morbimortality for abdominal aortic aneurysm</dc:title>
<dc:description xml:lang="en">Introduction: Due to the less invasive nature and good post-operative outcomes of endovascular treatment (EVAR) of abdominal aortic aneurysm (AAA), the number of patients treated by this method has increased. Objective: To evaluate the impact of EVAR on morbidity and mortality in the treatment of AAA. Methods: Observational and retrospective study of patients undergoing elective and emergency EVAR or open surgery (CA) for infrarenal AAA in our centre (January 2007-December 2014). An analysis was carried out on the mortality, early and long-term complications, re-operation for any cause, and due to endoleak in EVAR. An analysis of long-term survival was performed, and CA and EVAR groups were compared using routine biomedical tests. Results: A total of 286 patients who underwent infrarenal AAA repair were identified, of whom 80.1% (28.3 CA vs. 71.7% EVAR) were elective, and 19.1% emergency (77.2 CA vs. 22.8% EVAR). In patients undergoing elective procedures, a significantly higher mean age (68 vs. 76 years, P &lt;.05), and shorter mean post-operative hospital stay (11 vs. 5 days, P &lt;.05) was observed with EVAR. Thirty-day mortality (4.6 CA vs. 0.6% EVAR, P &lt;.05) and complications (20 CA vs. 7.9% EVAR, P &lt;.05) were lower in EVAR, but the number of re-interventions was higher (1.6 CA vs. 12.2% EVAR, P &lt;.05) during the follow up, with no difference in late mortality (25.8 CA vs. 27.4% EVAR). In emergency procedures, cardiological and respiratory complications were more frequent in the CA group (28.3 CA, and 33.3 vs. 0% EVAR, respectively), with no difference in 30-day (31.8 CA vs. 23.1 EVAR) or late mortality (40 CA vs. 40% EVAR). Conclusion: Patients undergoing elective EVAR have a significantly lower 30-day morbidity and mortality than those undergoing CA. On the other hand, the long-term mortality was comparable, with a higher re-intervention rate in EVAR. More cardiorespiratory complications were found in CA than in emergency EVAR, with no difference in 30-day or late mortality (AU)</dc:description>
<dc:creator>Ruiz Díaz, E</dc:creator>
<dc:creator>García Colodro, JM</dc:creator>
<dc:creator>Pena Holguín, J</dc:creator>
<dc:creator>Martínez Gallego, EL</dc:creator>
<dc:creator>Durán Mariño, JL</dc:creator>
<dc:creator>Pulpeiro Ríos, JR</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: Debido al carácter menos invasivo y a los buenos resultados postoperatorios del tratamiento endovascular (EVAR) del aneurisma de aorta abdominal (AAA), han aumentado el número de AAA tratados mediante este procedimiento. Objetivo: Evaluar el impacto del EVAR en la morbimortalidad del tratamiento por AAA. Material y métodos: Estudio observacional y retrospectivo de pacientes tratados mediante EVAR o cirugía abierta (CA) por AAA infrarrenal en nuestro centro, tanto programados como urgentes (de enero de 2007 a diciembre de 2014). Analizamos mortalidad, complicaciones durante el postoperatorio inmediato y seguimiento, reintervenciones por cualquier causa y por fuga en EVAR. Se realiza un análisis de supervivencia a largo plazo y se comparan ambos grupos de CA y EVAR usando los test biomédicos habituales. Resultados: Realizamos 286 intervenciones por AAA infrarrenal: 80,1% programadas (28,3 CA vs. 71,7% EVAR) y 19,9% urgentes (77,2 CA vs. 22,8% EVAR). En las programados, la edad media era significativamente mayor (68 vs. 76 años; p &lt; 0,05) y la estancia media postoperatoria, menor (11 vs. 5 días; p &lt; 0,05) en EVAR. La mortalidad (4,6 CA vs. 0,6% EVAR; p &lt; 0,05) y las complicaciones (20 CA vs. 7,9% EVAR; p&lt;0,05) a 30días fueron menores en EVAR, con mayor número de reintervenciones en el seguimiento (1,6 CA vs. 12,2% EVAR; p &lt; 0,05), pero sin diferencias en la mortalidad tardía (25,8 CA vs. 27,4% EVAR). En urgentes, observamos más complicaciones cardiológicas y respiratorias en CA (25 y 31,8 CA vs. 0% EVAR), sin diferencias en mortalidad a 30días (31,8 CA vs. 23,1% EVAR) ni en el seguimiento (40 CA vs. 40% EVAR). Conclusión: Los pacientes tratados mediante EVAR electivo presentan una morbimortalidad a 30 días significativamente menor que los tratados mediante CA, resultados que son comparables en cuanto a mortalidad en el seguimiento, con mayor número de reintervenciones en EVAR. Observamos más complicaciones cardiorrespiratorias en CA que en EVAR urgente, sin diferencias en la mortalidad a 30 días ni en el seguimiento (AU)</dc:description>
<dc:source>Angiologia;69(3): 147-153, mayo.-jun. 2017. tab, graf</dc:source>
<dc:identifier>ibc-164476</dc:identifier>
<dc:title xml:lang="es">Impacto del tratamiento endovascular en la morbimortalidad por aneurisma de aorta abdominal</dc:title>
<dc:subject>^d28380</dc:subject>
<dc:subject>^d28418</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d11622^s22080</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d30829^s22009</dc:subject>
<dc:subject>^d54238^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201706</dc:date>
</metadata>
</record>
</ibecs-document>
